Medpace Holdings, Inc.
MEDP Large CapHealthcare · Diagnostics & Research
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Medpace Holdings, Inc. en bref
Medpace Holdings, Inc. (MEDP) is currently trading at 401,19 € with a market capitalization of 11,5 Md €. The trailing P/E ratio stands at 28.98x, with a forward P/E of 24.79x. The 52-week range spans from 263,19 € to 548,27 €; the current price is 26.8% below the yearly high. Year-over-year revenue growth stands at +26.5%. The net profit margin stands at 17.19%.
💰 Dividende
Medpace Holdings, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
12 analystes évaluent Medpace Holdings, Inc. (MEDP) au consensus : Conserver. L'objectif de cours moyen est de 386,04 €, soit un potentiel de -3.77% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 286,81 € à 431,52 €.
Medpace Holdings, Inc. : la thèse d'investissement en détail
Medpace Holdings, Inc. (MEDP) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 26.5% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 71.9%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 77.25% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.
À surveiller
- The forward P/E of 24.79x is meaningfully below the trailing 28.98x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 26.5% sur un an
- Rentabilité élevée des capitaux propres (77.25% ROE)
- Marge brute élevée de 71.9% — signe d'un pouvoir de fixation des prix
- Bilan solide avec faible endettement (D/E 24.42)
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (8.93%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Medpace Holdings, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news